{
    "2021-04-27": [
        [
            {
                "time": "",
                "original_text": "东吴证券维持天坛生物买入评级，2020年报及2021年一季报点评：业绩符合预期，血制品业务持续增长",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "买入评级",
                        "2020年报",
                        "2021一季报",
                        "血制品业务",
                        "业绩增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "真心看好：“千亿顶流”连续四个季度大手笔加仓这个赛道",
                "features": {
                    "keywords": [
                        "千亿顶流",
                        "加仓",
                        "赛道"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "未明确"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "天坛生物（600161）：疫情影响基本消退 采浆量和吨浆效率仍具成长空间",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "疫情影响",
                        "采浆量",
                        "吨浆效率",
                        "成长空间"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国元证券：天坛生物（600161.SH）定增落地助力新产能+新产品，维持“增持”评级",
                "features": {
                    "keywords": [
                        "国元证券",
                        "天坛生物",
                        "定增落地",
                        "新产能",
                        "新产品",
                        "增持评级"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "国元证券给予天坛生物增持评级，天坛生物2020年报&2021年一季报点评：业绩恢复高增长，定增落地助力新产能+新产品",
                "features": {
                    "keywords": [
                        "国元证券",
                        "天坛生物",
                        "增持评级",
                        "2020年报",
                        "2021一季报",
                        "业绩高增长",
                        "定增落地",
                        "新产能",
                        "新产品"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "每日“药”闻|百济神州2020年亏损15.97亿美金；长效RSV抗体三期临床成功",
                "features": {
                    "keywords": [
                        "百济神州",
                        "亏损",
                        "RSV抗体",
                        "三期临床成功"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "艾尔建又有医美新品；参天全球最大生产基地开工；天坛生物非公开发行A股",
                "features": {
                    "keywords": [
                        "艾尔建",
                        "医美新品",
                        "参天",
                        "生产基地",
                        "天坛生物",
                        "非公开发行A股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "医美"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}